Traders Buy High Volume of Oncology Institute Call Options (NASDAQ:TOI)

The Oncology Institute, Inc. (NASDAQ:TOI) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 7,930 call options on the company. This represents an increase of approximately 435% compared to the average volume of 1,482 call options.

Insider Buying and Selling at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 6,018,168 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $18,596,139.12. Following the sale, the director directly owned 7,932,389 shares of the company’s stock, valued at approximately $24,511,082.01. This represents a 43.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd boosted its stake in Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock worth $63,000 after buying an additional 18,448 shares during the period. WealthShield Partners LLC purchased a new position in shares of Oncology Institute during the first quarter worth about $80,000. Citizens Financial Group Inc. RI purchased a new stake in Oncology Institute in the first quarter valued at approximately $71,000. Josh Arnold Investment Consultant LLC acquired a new stake in shares of Oncology Institute during the first quarter worth about $2,267,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Oncology Institute in the first quarter valued at approximately $131,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Trading Down 8.6%

NASDAQ:TOI traded down $0.33 during midday trading on Wednesday, hitting $3.45. The stock had a trading volume of 2,574,660 shares, compared to its average volume of 1,647,278. Oncology Institute has a one year low of $0.13 and a one year high of $4.88. The stock has a 50-day moving average of $3.78 and a 200 day moving average of $3.35. The company has a market capitalization of $322.11 million, a price-to-earnings ratio of -5.41 and a beta of 0.07. The company has a quick ratio of 1.39, a current ratio of 1.68 and a debt-to-equity ratio of 14.58.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The business had revenue of $136.56 million for the quarter, compared to analyst estimates of $122.63 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 13.21%. Oncology Institute has set its FY 2025 guidance at EPS.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TOI shares. BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research note on Tuesday, October 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, October 8th. Finally, Noble Financial initiated coverage on shares of Oncology Institute in a research report on Wednesday, July 23rd. They set an “outperform” rating and a $8.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.